A Phase 1 First-In-Human Study Evaluating Safety, Pharmacokinetics, and Efficacy of ABBV-291 in Non-Hodgkin's Lymphoma
Latest Information Update: 06 Nov 2024
Price :
$35 *
At a glance
- Drugs ABBV-291 (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors AbbVie
- 06 Nov 2024 New trial record